MedTrace Logo

Simultaneous Integrated Boost (SIB)- IMRT

NCT00389727 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2019-07-15

No results posted yet for this study

Summary

The objective of the study is to assess the feasibility of increasing dose of irradiation with IMRT using a SIB approach over 6 weeks.

The primary endpoint of the study will be acute toxicity assessed during treatment and during the first 3 months following the completion of radiotherapy The secondary endpoint will include loco-regional control, disease-free survival, survival and late toxicity at 2 years after completion of radiotherapy

Conditions

  • Carcinoma, Squamous Cell

Interventions

DRUG

Radiotherapy

Radiotherapy

Sponsors & Collaborators

  • Centre Georges Francois Leclerc

    collaborator OTHER

  • Cliniques universitaires Saint-Luc- Université Catholique de Louvain

    lead OTHER

Principal Investigators

  • Vincent Gregoire, MD, PhD · Cliniques universitaires Saint Luc Brussels Belgium

  • Philippe Maingon, MD, PhD · Centre George-François Leclerc Dijon, France

  • Sandra Nuyts, MD · University hospital Gasthuisberg, Katholiek universiteit van Leuven

  • Gilles Calais, MD, PhD · CHU de Tours, Bretonneau

  • Antoine Serre, MD · centre Val d'Aurelle, Montpellier

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-09-24
Primary Completion
2008-05-26
Completion
2008-05-26

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00389727 on ClinicalTrials.gov